Tags

Type your tag names separated by a space and hit enter

Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.
Osteoporos Int. 2010 Jan; 21(1):157-65.OI

Abstract

The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women.

INTRODUCTION

This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporotic women.

METHODS

A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score <or= -2.5 SD or with prevalent vertebral fractures. The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment. Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analyses.

RESULTS

Strontium ranelate was cost-saving at the age of 80 years in both populations. For women with a T-score <or= -2.5 SD, the costs per QALY gained of strontium ranelate were respectively euro 15,096 euro and 6,913 euro at 70 and 75 years of age while these values were 23,426 euro and 9,698 euro for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions.

CONCLUSION

This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporotic women.

Authors+Show Affiliations

Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. m.hiligsmann@ulg.ac.beNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19350339

Citation

Hiligsmann, M, et al. "Cost-utility of Long-term Strontium Ranelate Treatment for Postmenopausal Osteoporotic Women." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 21, no. 1, 2010, pp. 157-65.
Hiligsmann M, Bruyère O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int. 2010;21(1):157-65.
Hiligsmann, M., Bruyère, O., & Reginster, J. Y. (2010). Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 21(1), 157-65. https://doi.org/10.1007/s00198-009-0924-z
Hiligsmann M, Bruyère O, Reginster JY. Cost-utility of Long-term Strontium Ranelate Treatment for Postmenopausal Osteoporotic Women. Osteoporos Int. 2010;21(1):157-65. PubMed PMID: 19350339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. AU - Hiligsmann,M, AU - Bruyère,O, AU - Reginster,J-Y, Y1 - 2009/04/07/ PY - 2008/11/21/received PY - 2009/03/24/accepted PY - 2009/4/8/entrez PY - 2009/4/8/pubmed PY - 2011/1/14/medline SP - 157 EP - 65 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 21 IS - 1 N2 - UNLABELLED: The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women. INTRODUCTION: This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporotic women. METHODS: A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score <or= -2.5 SD or with prevalent vertebral fractures. The relative risk of fracture during therapy was derived from the Treatment of Peripheral Osteoporosis Study trial over 5 years of treatment. Parameter uncertainty was evaluated using both univariate and probabilistic sensitivity analyses. RESULTS: Strontium ranelate was cost-saving at the age of 80 years in both populations. For women with a T-score <or= -2.5 SD, the costs per QALY gained of strontium ranelate were respectively euro 15,096 euro and 6,913 euro at 70 and 75 years of age while these values were 23,426 euro and 9,698 euro for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions. CONCLUSION: This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporotic women. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/19350339/Cost_utility_of_long_term_strontium_ranelate_treatment_for_postmenopausal_osteoporotic_women_ L2 - https://doi.org/10.1007/s00198-009-0924-z DB - PRIME DP - Unbound Medicine ER -